M&A Deal Summary |
|
|---|---|
| Date | 2025-06-23 |
| Target | Plasma Services Group |
| Sector | Medical Products |
| Buyer(s) | Fujirebio |
| Deal Type | Add-on Acquisition |
| Advisor(s) | Achelous Partners (Financial) |
SEARCH BY
Fujirebio focused on developing and marketing CSF biomarkers for Alzheimer’s disease testing, under the Innogenetics brand, over 25 years ago. It remains the only company with such a comprehensive line-up of manual and fully automated AD assays and consistently partners with organizations and clinical experts across the world to develop new pathways for earlier, easier, and more complete neurodegenerative diagnostic tools. Fujirebio was formed in 1950 and is based in Tokyo, Japan.
| DEAL STATS | # |
|---|---|
| Overall | 2 of 2 |
| Sector: Medical Products M&A | 1 of 1 |
| Type: Add-on Acquisition M&A Deals | 2 of 2 |
| State: New Jersey M&A | 1 of 1 |
| Country: United States M&A | 1 of 1 |
| Year: 2025 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2022-06-23 |
ADx NeuroSciences
Gent, Belgium ADx NeuroSciences is an R&D-driven company specializing in the development of neurodegenerative biomarkers. Its expertise is used by pharmaceutical and diagnostic companies for the conception, development, production, and worldwide commercialization of novel biomarkers. These collaborations result in new diagnostic assays that support the development of promising drugs either by monitoring the drug effect or by selecting the right patients at a very early stage of the disease. These assays are used in neurodegenerative diseases like Alzheimer’s disease and Parkinson’s and can be applied to a variety of platforms for research up to IVD use. ADx NeuroSciences was formed in 2011 and is based in Gent, Belgium. |
Buy | €40M |
